The DNA vaccine
in this report refers to the vaccines manufactured using recombinant DNA technology.
VGXI's proprietary plasmid manufacturing process is recognized for providing the highest purity and supercoil fraction for DNA-based pharmaceuticals, in particular DNA vaccines
. To meet urgent patient needs, this process will be optimized to enable turnaround times 1/10 of that for standard GMP grade products without compromising product quality.
Thus, a novel SS DNA vaccine-fused CpG motifs should be constructed, and its effects in promoting the growth of animals should be evaluated to improve the efficiency and reduce the cost of SS DNA vaccine
In preclinical studies, ITI-7000, an investigational DNA vaccine
targeting ErbB2/HER2, demonstrated robust activation of known anti-tumor CD4 and CD8 cells in vivo and promoted tumor infiltration with activated CD8 T cells.
N4 Pharma, which is developing silica nanoparticles for vaccines and therapeutics, has commissioned a research programme with UoA's Gowans laboratory to investigate the potential of the company's Nuvec system to increase the efficacy of the university's novel cytolytic DNA vaccine
major after DNA vaccine
using a cocktail of plasmids (18).
To first compare the immunogenicity and protective efficacy of the individual optimized VEEV DNA vaccine
to that of a 1 : 1 : 1 mixture of the optimized VEEV, WEEV, and EEEV DNA vaccines
(3-EEV DNA vaccine
), female BALB/c mice (n = 10 per group) were vaccinated on days 0 and 21 with 5 [micro]g of the VEEV plasmid or with 5 [micro]g of each of the VEEV, WEEV, and EEEV plasmids (15 [micro]g total) by IM EP.
Since the method was employed during the SARS epidemic of 2003, the time from sequence selection to a phase 1 trial has gone from 20 months to 3.25 months (for the Zika DNA vaccine
Acuna et al., "Protective effect of a DNA vaccine
containing an open reading frame with homology to an ABC-type transporter present in the genomic island 3 of Brucella abortus in BALB/c mice," Vaccine, vol.
In order to develop novel therapeutics specifically targeting CTLA-4, we constructed a DNA vaccine
by cloning the sequence of human CTLA-4 fused with PSCA gene into pVAX1.
do not contain infectious material--so they cannot cause a vaccinated individual to become infected with Zika--and have been shown to be safe in previous clinical trials for other diseases.
In the present study, the IBV S1 and li-key segment of chicken major histocompatibility complex II gene were used to construct the recombinant plasmids that the DNA vaccine
optimum response could be achieved.